Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:BRNSNASDAQ:CVKDNASDAQ:HCWB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$6.90+2.8%$8.48$7.96▼$24.15$34.80M0.6316,152 shs131,722 shsBRNSBarinthus Biotherapeutics$1.12+12.0%$0.89$0.64▼$2.45$40.34M-0.7733,555 shs39,864 shsCVKDCadrenal Therapeutics$16.42-2.1%$17.34$5.70▼$22.90$31.86M1.4238,883 shs14,529 shsHCWBHCW Biologics$8.06+7.2%$11.10$6.65▼$100.80$9.05M0.8297,921 shs14,709 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+0.15%+1.51%-21.98%-31.18%-64.18%BRNSBarinthus Biotherapeutics+19.18%+32.44%-4.77%+5.25%-61.39%CVKDCadrenal Therapeutics-3.34%+0.24%-9.10%-9.49%+1,677,999,900.00%HCWBHCW Biologics-2.44%-7.16%-38.42%-28.70%-86.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ABRNSBarinthus Biotherapeutics2.3447 of 5 stars3.53.00.00.02.30.01.3CVKDCadrenal Therapeutics3.2724 of 5 stars3.55.00.00.03.31.70.6HCWBHCW Biologics1.0035 of 5 stars0.05.00.00.02.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ABRNSBarinthus Biotherapeutics 3.00Buy$5.17361.31% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.0094.88% UpsideHCWBHCW Biologics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HCWB, BRNS, ALVR, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025BRNSBarinthus BiotherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/21/2025BRNSBarinthus BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ABRNSBarinthus Biotherapeutics$14.97M3.02N/AN/A$4.85 per share0.23CVKDCadrenal TherapeuticsN/AN/AN/AN/A$8.86 per shareN/AHCWBHCW Biologics$2.57M3.53N/AN/A$0.37 per share21.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%5/12/2025 (Estimated)BRNSBarinthus Biotherapeutics-$73.35M-$1.55N/AN/AN/AN/A-34.26%-29.30%5/12/2025 (Estimated)CVKDCadrenal Therapeutics-$8.36M-$8.67N/AN/AN/AN/A-142.95%-118.40%5/8/2025 (Estimated)HCWBHCW Biologics-$24.99M-$31.20N/A∞N/A-1,067.82%-2,516.84%-132.95%5/21/2025 (Estimated)Latest HCWB, BRNS, ALVR, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34N/AN/AN/AN/AN/A5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64N/AN/AN/AN/AN/A3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 million3/20/2025Q4 2024BRNSBarinthus Biotherapeutics-$0.50-$0.51-$0.01-$0.51N/A$14.97 million3/13/2025Q4 2024CVKDCadrenal Therapeutics-$1.71-$2.74-$1.03-$2.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78BRNSBarinthus BiotherapeuticsN/A8.938.93CVKDCadrenal TherapeuticsN/A3.693.69HCWBHCW BiologicsN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%BRNSBarinthus Biotherapeutics25.20%CVKDCadrenal Therapeutics7.92%HCWBHCW Biologics2.96%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%BRNSBarinthus Biotherapeutics8.00%CVKDCadrenal Therapeutics48.62%HCWBHCW Biologics49.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableBRNSBarinthus Biotherapeutics10740.34 million37.01 millionN/ACVKDCadrenal Therapeutics41.94 million916,000Not OptionableHCWBHCW Biologics401.12 million22.32 millionNot OptionableHCWB, BRNS, ALVR, and CVKD HeadlinesRecent News About These CompaniesHCW Biologics faces lawsuit over construction contract breachApril 24, 2025 | investing.comHcw Biologics Inc trading halted, news pendingApril 11, 2025 | markets.businessinsider.comHCW Biologics files to sell 7.1M shares of common stock for holdersApril 8, 2025 | markets.businessinsider.comHCW Biologics approves reverse stock split to meet Nasdaq rulesApril 3, 2025 | investing.comHCW Biologics approves 1-for-40 reverse stock splitApril 2, 2025 | markets.businessinsider.comHCW Biologics Announces 1-for-40 Reverse Stock SplitApril 1, 2025 | globenewswire.comHCW Biologics, Inc: HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial ResultsMarch 29, 2025 | finanznachrichten.deHCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial ResultsMarch 28, 2025 | finance.yahoo.comHCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial ResultsMarch 28, 2025 | globenewswire.comHCW Biologics amends agreement with WY Biotech amid delaysMarch 21, 2025 | investing.comHCW Biologics, Inc: HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing RequirementsMarch 6, 2025 | finanznachrichten.deHCW Biologics granted extension by Nasdaq to regain listing complianceMarch 6, 2025 | markets.businessinsider.comHCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing RequirementsMarch 6, 2025 | globenewswire.comHCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areataFebruary 5, 2025 | pharmabiz.comHcw Biologics Inc (HCWB) Stock: Surpassing Expectations in the Market?February 4, 2025 | bovnews.comFDA approves HCW Biologics trial for alopecia treatmentFebruary 3, 2025 | msn.comHCW Biologics receives clearance of IND from FDA for HCW9302February 3, 2025 | markets.businessinsider.comPharma company granted FDA clearance for alopecia drug studyFebruary 3, 2025 | bizjournals.comHCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical TrialFebruary 3, 2025 | markets.businessinsider.comHCW Biologics Inc. Receives FDA Clearance for IND Application to Initiate Phase 1 Clinical Trial of HCW9302 for Alopecia AreataFebruary 3, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCWB, BRNS, ALVR, and CVKD Company DescriptionsAlloVir NASDAQ:ALVR$6.90 +0.19 (+2.83%) As of 04/29/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Barinthus Biotherapeutics NASDAQ:BRNS$1.12 +0.12 (+12.01%) As of 03:59 PM EasternBarinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Cadrenal Therapeutics NASDAQ:CVKD$16.42 -0.36 (-2.15%) As of 04:00 PM EasternCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.HCW Biologics NASDAQ:HCWB$8.06 +0.54 (+7.18%) As of 03:56 PM EasternHCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
